Cellestia is a clinical stage R&D company developing innovative first-in-class therapies to control and modulate pathogenic gene expression in multiple disease areas by selective inhibition of transcription factors in the cell nucleus. The lead compound CB-103 has advanced to Phase 2 successfully treating patients with multi-drug resistant cancers.
Further, Cellestia is advancing a rich R&D pipeline of novel transcription factor inhibitors, in oncology, auto-immune and inflammatory disorders, having achieved animal in-vivo proof of concept for several new targets. Cellestia was founded in 2014 as a spin-off from EPFL, Lausanne, Switzerland and is headquartered in Basel, Switzerland.
WE ARE RELENTLESS IN OUR PURSUIT OF
Pioneering science
We aspire to address unmet medical needs by developing innovative first-in-class therapies which can make previously undruggable targets druggable.
WE ARE RESOLUTE IN OUR
Dedication to patients
There is no compromise to our dedication to the patients we serve. We put their needs first and are resolute in our search for groundbreaking novel therapies.
WE EXTEND AND IMPROVE
Quality of life
We are developing safe and therapeutic solutions to extend and improve the quality of life for patients who currently have no other treatment options.
WE ASPIRE TO
Cure cancer
We aspire to reach true breakthroughs in cancer treatments and therapies that will ultimately lead to a cure for previously incurable cancers.
WE DO WHATEVER IT TAKEs TO
Shape the future
We hold each other responsible and accountable to the vision and goals we share as we carve our own path forward.
We are all in
History
Based on more than 10 years of academic research led by the company’s CSO, Rajwinder Lehal, Cellestia was founded in 2014 as spin-off from the prestigious Swiss Institute for Experimental Cancer Research (ISREC), based at the École Polytechnique Fédérale de Lausanne (EPFL), a world-renowned centre of excellence in Switzerland. Originally incubated at ISREC, today Cellestia has established its independent research facilities at Biopôle in Lausanne and in close proximity to Ludwig Institute for Cancer Research, Swiss Cancer Center Léman, Le Centre hospitalier universitaire vaudois (CHUV), and University of Lausanne and EPFL. In addition, multiple international research collaborations have been established.
2012
First patent application filed
2015
Michael Bauer joins
and the HQ move to Basel
2017
IND filed
Mode of action identified
2019
Safety and Efficacy Data
Series B completed
2021
Start of Phase II Oncology
Global Expansion of Development Program CB-103
2008
Transcription Factors Inhibitors Research starts with Raj Lehal’s doctoral thesis
2014
Foundation of Cellestia in Lausanne
2016
CB-103 development begins
First series financing and team expansion
2018
Start of Clinical Development in Oncology
Series A completed
2020
Clinical Proof of Concept CB-103
History
2008
Transcription Factors Inhibitors Research starts with Raj Lehal’s doctoral thesis
2012
First patent application filed
2014
Foundation of Cellestia in Lausanne
2015
Michael Bauer joins
and the HQ move to Basel
2016
• CB-103 development begins
• First series financing and team expansion
2017
• IND filed
• Mode of action identified
2018
• Start of Clinical Development in Oncology
• Series A completed
2019
• Safety and Efficacy Data
• Series B completed
2020
Clinical Proof of Concept CB-103
2021
• Start of Phase II Oncology
• Global Expansion of Development Program CB-103
If my research can make a difference for even one single patient, I would consider this the reward of my lifetime.
Cellestia is the first company to control NOTCH-positive cancers safely and effectively in any cancer patient, closing a major gap in today’s cancer therapy.
Clinical & Research Collaboration
Cellestia has established a global clinical development and research collaboration with Europe, US and Asia.
